Abstract
Herpes simplex viruses (HSVs) have entered clinical trials as oncolytic agents. The following properties make them good candidates. It is a mild pathogen; drugs (Aciclovir) are available to control viral infection; the large genome is amenable to genetic engineering, they can be rendered cancer-specific by deletion of genes, envelope glycoproteins allow the insertion of heterologous ligands to achieve modification of the natural tropism. Genetically modified HSVs have been thoroughly tested in humans. New generation recombinants retargeted to cancer-specific heterologous receptors have been generated and are presently evaluated in pre-clinical settings. They will be reviewed along with the molecular bases of cancer specificity and the strategies for the enhancement of oncolytic potential of HSV recombinants.
Keywords: Herpes simplex virus, oncolytic virus, oncolytic virotherapy, glioma, γ1 34.5, HER-2, mild pathogen, natural tropism, cancer specificity, HSV recombinants
Current Pharmaceutical Biotechnology
Title:The Molecular Basis of Herpesviruses as Oncolytic Agents
Volume: 13 Issue: 9
Author(s): Laura Menotti, Gabriella Campadelli-Fiume, Patrizia Nanni, Pier Luigi Lollini and Carla De Giovanni
Affiliation:
Keywords: Herpes simplex virus, oncolytic virus, oncolytic virotherapy, glioma, γ1 34.5, HER-2, mild pathogen, natural tropism, cancer specificity, HSV recombinants
Abstract: Herpes simplex viruses (HSVs) have entered clinical trials as oncolytic agents. The following properties make them good candidates. It is a mild pathogen; drugs (Aciclovir) are available to control viral infection; the large genome is amenable to genetic engineering, they can be rendered cancer-specific by deletion of genes, envelope glycoproteins allow the insertion of heterologous ligands to achieve modification of the natural tropism. Genetically modified HSVs have been thoroughly tested in humans. New generation recombinants retargeted to cancer-specific heterologous receptors have been generated and are presently evaluated in pre-clinical settings. They will be reviewed along with the molecular bases of cancer specificity and the strategies for the enhancement of oncolytic potential of HSV recombinants.
Export Options
About this article
Cite this article as:
Menotti Laura, Campadelli-Fiume Gabriella, Nanni Patrizia, Luigi Lollini Pier and De Giovanni Carla, The Molecular Basis of Herpesviruses as Oncolytic Agents, Current Pharmaceutical Biotechnology 2012; 13 (9) . https://dx.doi.org/10.2174/138920112800958931
DOI https://dx.doi.org/10.2174/138920112800958931 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Natural Monophenols as Therapeutics, Antioxidants and Toxins; Electron Transfer, Radicals and Oxidative Stress
The Natural Products Journal Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Influence of Trishomocubanes on Sigma Receptor Binding of N-(1-Benzylpiperidin- 4-yl)-4-[123I]iodobenzamide In Vivo in the Rat Brain
Medicinal Chemistry Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning
Central Nervous System Agents in Medicinal Chemistry Targeting Ion Channels in Cancer: A Novel Frontier in Antineoplastic Therapy
Current Medicinal Chemistry Application of Targeted Therapy to Malignant Gliomas and Response to Treatment
Current Signal Transduction Therapy Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Monocarboxylate Transporter 1 in Brain Diseases and Cancers
Current Drug Metabolism Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs
Drug Metabolism Letters The Bacterial lux Reporter System: Applications in Bacterial Localisation Studies
Current Gene Therapy E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design